Jaurigue Jonnel A, Seeberger Peter H
Department of Biomolecular Systems, Max Planck Institute of Colloids and InterfacesPotsdam, Germany.
Institute for Chemistry and Biochemistry, Freie Universität BerlinBerlin, Germany.
Front Cell Infect Microbiol. 2017 Jun 12;7:248. doi: 10.3389/fcimb.2017.00248. eCollection 2017.
Vaccination is an efficient means of combating infectious disease burden globally. However, routine vaccines for the world's major human parasitic diseases do not yet exist. Vaccines based on carbohydrate antigens are a viable option for parasite vaccine development, given the proven success of carbohydrate vaccines to combat bacterial infections. We will review the key components of carbohydrate vaccines that have remained largely consistent since their inception, and the success of bacterial carbohydrate vaccines. We will then explore the latest developments for both traditional and non-traditional carbohydrate vaccine approaches for three of the world's major protozoan parasitic diseases-malaria, toxoplasmosis, and leishmaniasis. The traditional prophylactic carbohydrate vaccine strategy is being explored for malaria. However, given that parasite disease biology is complex and often arises from host immune responses to parasite antigens, carbohydrate vaccines against deleterious immune responses in host-parasite interactions are also being explored. In particular, the highly abundant glycosylphosphatidylinositol molecules specific for , and spp. are considered exploitable antigens for this non-traditional vaccine approach. Discussion will revolve around the application of these protozoan carbohydrate antigens for vaccines currently in preclinical development.
疫苗接种是全球对抗传染病负担的有效手段。然而,针对世界主要人类寄生虫病的常规疫苗尚未问世。鉴于碳水化合物疫苗在对抗细菌感染方面已被证实的成功,基于碳水化合物抗原的疫苗是寄生虫疫苗开发的一个可行选择。我们将回顾自碳水化合物疫苗诞生以来基本保持一致的关键组成部分,以及细菌碳水化合物疫苗的成功案例。然后,我们将探讨针对世界上三种主要原生动物寄生虫病——疟疾、弓形虫病和利什曼病——的传统和非传统碳水化合物疫苗方法的最新进展。正在探索针对疟疾的传统预防性碳水化合物疫苗策略。然而,鉴于寄生虫疾病生物学复杂,且往往源于宿主对寄生虫抗原的免疫反应,针对宿主-寄生虫相互作用中有害免疫反应的碳水化合物疫苗也在探索之中。特别是,针对疟原虫属和利什曼原虫属的高度丰富的糖基磷脂酰肌醇分子被认为是这种非传统疫苗方法可利用的抗原。讨论将围绕这些原生动物碳水化合物抗原在目前处于临床前开发阶段的疫苗中的应用展开。